JP2010508265A - G−csfを含有する、糖尿性末梢神経病予防および治療剤 - Google Patents
G−csfを含有する、糖尿性末梢神経病予防および治療剤 Download PDFInfo
- Publication number
- JP2010508265A JP2010508265A JP2009534501A JP2009534501A JP2010508265A JP 2010508265 A JP2010508265 A JP 2010508265A JP 2009534501 A JP2009534501 A JP 2009534501A JP 2009534501 A JP2009534501 A JP 2009534501A JP 2010508265 A JP2010508265 A JP 2010508265A
- Authority
- JP
- Japan
- Prior art keywords
- csf
- nerve
- peripheral neuropathy
- diabetic peripheral
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
G−CSF(Granulocyte−Colony Stimulating Factor)を有効成分として含む糖尿性末梢神経病予防および治療剤と末梢神経再生剤を提供することを課題とする。
【解決手段】
末梢神経組織から血管を再生し破壊された神経組織を修復することによって、神経伝達速度および痛みの敏感度を好転させる顆粒球コロニー刺激因子(granulocyte colony stimulating factor, G−CSF)を有効成分として含む糖尿性末梢神経病の予防および治療剤を開示する。
【選択図】図1
Description
したがって、糖尿性末梢神経病の病因機転研究およびこれに基づいた根本的な薬剤開発が切実に求められている状況である。
本発明の他の目的はG−CSF(granulocyte colony stimulating factor)を有効成分として含む末梢神経再生剤を提供することにある。
本発明者らは顆粒球コロニー刺激因子(granulocyte colony stimulating factor, 以下‘G−CSF’という。)の多様な生理活性を研究しているなかで、G−CSFが末梢神経組織で血管を再生し破壊された神経組織を修復することによって神経伝達速度および痛みの敏感度を改善することにより、糖尿性末梢神経病の予防および治療剤として有用に使用できる可能性があることを発見し、これを基に本発明を完成することとなった。
実施例1:G−CSFの糖尿性末梢神経病の治療効果を確認するための動物実験
文献[Nakamura Jなど,Diabetes Research Clinical Practice, 2001 Jan;51(1):9−20]に記述されたものと類似の方法を使い、糖尿性末梢神経症動物モデルを作った。
本発明の糖尿性末梢神経病の治療効果を把握するために、糖尿性末梢神経病患者を対象として臨床実験を実施した。
本評価は、下記の表6に示したToronto Clinical Neuropathy Scoring Systemに記載された項目などを測定し評価した。この時各項目に対して点数を合算し示すことによって、最高の点数は19点、最低の点数は0点であって、この時点数が高いほど糖尿性末梢神経症の程度が激しいことを意味する。得られた結果は下記の表7および図7に示した。
Claims (6)
- G−CSF(Glanulocyte−Colony Stimulating Factor)を有効成分として含む糖尿性末梢神経病予防および治療剤。
- 前記G−CSFが天然または再調合起源から収得し分離されることを特徴とする請求項1に記載の糖尿性末梢神経病予防および治療剤。
- 前記G−CSFは再調合ヒト顆粒球コロニー刺激因子(rhG−CSF)であることを特徴とする請求項1に記載の糖尿性末梢神経病予防および治療剤。
- G−CSF(Glanulocyte−Colony Stimulating Factor)を有効成分として含む末梢神経再生剤。
- 前記G−CSFが天然または再調合起源から収得し分離されることを特徴とする請求項4に記載の末梢神経再生剤。
- 前記G−CSFは再調合ヒト顆粒球コロニー刺激因子(rhG−CSF)であることを特徴とする請求項に4記載の末梢神経再生剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2006-0105684 | 2006-10-30 | ||
KR1020060105684A KR100812274B1 (ko) | 2006-10-30 | 2006-10-30 | G-csf를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제 |
PCT/KR2007/005353 WO2008054098A1 (en) | 2006-10-30 | 2007-10-29 | Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010508265A true JP2010508265A (ja) | 2010-03-18 |
JP5416589B2 JP5416589B2 (ja) | 2014-02-12 |
Family
ID=39344418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009534501A Expired - Fee Related JP5416589B2 (ja) | 2006-10-30 | 2007-10-29 | G−csfを含有する、糖尿性末梢神経病予防および治療剤 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20100048869A1 (ja) |
EP (1) | EP2077852B1 (ja) |
JP (1) | JP5416589B2 (ja) |
KR (1) | KR100812274B1 (ja) |
CN (1) | CN101528251B (ja) |
AU (1) | AU2007314854B2 (ja) |
BR (1) | BRPI0718099A2 (ja) |
CA (1) | CA2667178C (ja) |
ES (1) | ES2448837T3 (ja) |
HK (1) | HK1132461A1 (ja) |
MX (1) | MX2009004646A (ja) |
NZ (1) | NZ576498A (ja) |
PT (1) | PT2077852E (ja) |
RU (1) | RU2448726C2 (ja) |
UA (1) | UA93581C2 (ja) |
WO (1) | WO2008054098A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021075536A1 (ja) * | 2019-10-18 | 2021-04-22 | 国立大学法人滋賀医科大学 | 幹細胞遊走剤を使用した糖尿病治療 |
WO2022181797A1 (ja) * | 2021-02-26 | 2022-09-01 | 国立大学法人滋賀医科大学 | 糖尿病および合併症の新規治療、診断および検出のための方法および剤 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100908628B1 (ko) * | 2008-03-21 | 2009-07-21 | 한양대학교 산학협력단 | G-csf를 유효성분으로 하는 외상성 말초신경 손상 치료용 조성물 |
KR20100020125A (ko) * | 2008-08-12 | 2010-02-22 | 한양대학교 산학협력단 | G-csf를 유효성분으로 하는 신경병증성 통증 예방 또는치료제 |
KR101032307B1 (ko) | 2008-10-02 | 2011-05-06 | 전북대학교병원 | 생체적합성 분자광학영상용 양자점 및 이의 제조방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0741429A (ja) * | 1993-07-30 | 1995-02-10 | Mitsubishi Chem Corp | 神経障害改善薬 |
JP2003113085A (ja) * | 1998-04-23 | 2003-04-18 | Takeda Chem Ind Ltd | 神経栄養因子様作用剤 |
JP2004131507A (ja) * | 1991-12-26 | 2004-04-30 | Chugai Pharmaceut Co Ltd | 脳機能障害による疾患の予防・治療薬 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1339071C (en) * | 1988-08-24 | 1997-07-29 | Koichiro Tsuji | Thrombus control agent |
WO2000062798A2 (en) * | 1999-04-15 | 2000-10-26 | St. Elizabeth's Medical Center, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
PT1129720E (pt) * | 2000-02-29 | 2004-08-31 | Pfizer Prod Inc | Factor estimulador de colonias de granulocitos estabilizado |
JP3968347B2 (ja) * | 2001-09-05 | 2007-08-29 | ヤマサ醤油株式会社 | 糖尿病性神経障害用医薬組成物 |
US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7695723B2 (en) * | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
CN1780642A (zh) * | 2003-04-15 | 2006-05-31 | 中外制药株式会社 | 糖尿病治疗剂 |
CN1321640C (zh) * | 2005-09-08 | 2007-06-20 | 南京医科大学 | 苄达赖氨酸在制备治疗糖尿病周围神经病变药物中的应用 |
-
2006
- 2006-10-30 KR KR1020060105684A patent/KR100812274B1/ko not_active IP Right Cessation
-
2007
- 2007-10-29 JP JP2009534501A patent/JP5416589B2/ja not_active Expired - Fee Related
- 2007-10-29 RU RU2009116833/15A patent/RU2448726C2/ru not_active IP Right Cessation
- 2007-10-29 US US12/447,798 patent/US20100048869A1/en not_active Abandoned
- 2007-10-29 MX MX2009004646A patent/MX2009004646A/es active IP Right Grant
- 2007-10-29 WO PCT/KR2007/005353 patent/WO2008054098A1/en active Application Filing
- 2007-10-29 ES ES07833661.7T patent/ES2448837T3/es active Active
- 2007-10-29 NZ NZ576498A patent/NZ576498A/en not_active IP Right Cessation
- 2007-10-29 CN CN2007800403392A patent/CN101528251B/zh not_active Expired - Fee Related
- 2007-10-29 CA CA2667178A patent/CA2667178C/en not_active Expired - Fee Related
- 2007-10-29 EP EP07833661.7A patent/EP2077852B1/en active Active
- 2007-10-29 BR BRPI0718099-3A patent/BRPI0718099A2/pt not_active Application Discontinuation
- 2007-10-29 UA UAA200904262A patent/UA93581C2/ru unknown
- 2007-10-29 AU AU2007314854A patent/AU2007314854B2/en not_active Ceased
- 2007-10-29 PT PT78336617T patent/PT2077852E/pt unknown
-
2010
- 2010-01-06 HK HK10100087.2A patent/HK1132461A1/xx not_active IP Right Cessation
- 2010-10-29 US US12/915,172 patent/US20110076247A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004131507A (ja) * | 1991-12-26 | 2004-04-30 | Chugai Pharmaceut Co Ltd | 脳機能障害による疾患の予防・治療薬 |
JPH0741429A (ja) * | 1993-07-30 | 1995-02-10 | Mitsubishi Chem Corp | 神経障害改善薬 |
JP2003113085A (ja) * | 1998-04-23 | 2003-04-18 | Takeda Chem Ind Ltd | 神経栄養因子様作用剤 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021075536A1 (ja) * | 2019-10-18 | 2021-04-22 | 国立大学法人滋賀医科大学 | 幹細胞遊走剤を使用した糖尿病治療 |
JPWO2021075536A1 (ja) * | 2019-10-18 | 2021-04-22 | ||
WO2022181797A1 (ja) * | 2021-02-26 | 2022-09-01 | 国立大学法人滋賀医科大学 | 糖尿病および合併症の新規治療、診断および検出のための方法および剤 |
Also Published As
Publication number | Publication date |
---|---|
JP5416589B2 (ja) | 2014-02-12 |
AU2007314854A1 (en) | 2008-05-08 |
CA2667178A1 (en) | 2008-05-08 |
CN101528251B (zh) | 2013-03-06 |
ES2448837T3 (es) | 2014-03-17 |
RU2009116833A (ru) | 2010-12-10 |
EP2077852B1 (en) | 2013-11-27 |
AU2007314854B2 (en) | 2014-01-16 |
US20100048869A1 (en) | 2010-02-25 |
CN101528251A (zh) | 2009-09-09 |
CA2667178C (en) | 2015-12-29 |
KR100812274B1 (ko) | 2008-03-13 |
WO2008054098A1 (en) | 2008-05-08 |
RU2448726C2 (ru) | 2012-04-27 |
US20110076247A1 (en) | 2011-03-31 |
EP2077852A1 (en) | 2009-07-15 |
MX2009004646A (es) | 2009-05-22 |
BRPI0718099A2 (pt) | 2013-11-05 |
NZ576498A (en) | 2012-03-30 |
EP2077852A4 (en) | 2012-01-18 |
PT2077852E (pt) | 2014-03-04 |
UA93581C2 (ru) | 2011-02-25 |
HK1132461A1 (en) | 2010-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090297470A1 (en) | Remedies for ischemia | |
EP1817047B1 (en) | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders | |
JP5416589B2 (ja) | G−csfを含有する、糖尿性末梢神経病予防および治療剤 | |
AU2004262909B2 (en) | Pharmaceutical combination of G-CSF and PlGF useful for blood stem cell | |
EP1146895A2 (en) | Thrombopoietin compositions for increasing circulating platelets | |
US20140294755A1 (en) | Materials and Methods Relating to Stem Cell Mobilization by Multi-Pegylated Granulocyte Colony Stimulating Factor | |
US8207116B2 (en) | Remedies for ischemia | |
CZ120298A3 (cs) | Použití proteinu získaného z chemokinu savců | |
NZ243953A (en) | Gm-csf composition for treating leukocyte dysfunction | |
SI21079A (sl) | Formulacija, ki povečuje mobilizacijo | |
KR20050114275A (ko) | 당뇨병 치료제 | |
JP7189399B2 (ja) | 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物 | |
US20070141053A1 (en) | Treatment of inflammatory respiratory diseases | |
EP0661057A1 (en) | Hematopoietic cell proliferation accelerator | |
US20110178016A1 (en) | Pulse parathyroid hormone for treatment of the hematopoietic syndrome, stromal cell loss, and vascular injury resulting from acute exposure to lethal radiation | |
JP2007070367A (ja) | Cml治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120717 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121016 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130117 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130619 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130619 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130619 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130821 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131022 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131115 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20150610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150611 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |